Influence of race and sociodemographic factors on declining resection for gastric cancer: A national study

Schultz, Kurt; Geus, Susanna W.L. de; Sachs, Teviah E.; Morgan, Ryan B.; Ng, Sing Chau; McAneny, David; Tseng, Jennifer F.

doi:10.1016/j.amjsurg.2020.06.022

Cited by 10 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies of refusal of surgery among patients with GI malignancies similarly demonstrated greater rates of refusal among patients treated at nonacademic centers. 47,48 As patients treated at nonacademic centers may have less comprehensive insurance coverage, 49 financial barriers may play a role in the decision to refuse treatment. Costs not captured by insurance coverage (eg, parking fees) may play a role.…”

Section: Discussionmentioning

confidence: 99%

Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma

Dee

Arega

Yang

et al. 2021

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: We assessed sociodemographic factors associated with and survival implications of refusal of potentially survival-prolonging locoregional treatment (LT, including radiotherapy and surgery) despite provider recommendation among men with localized prostate adenocarcinoma. METHODS: The National Cancer Database (2004-2015) identified men with TxN0M0 prostate cancer who either received or refused LT despite provider recommendation. Multivariable logistic regression defined adjusted odds ratios (AORs) with 95% CI of refusing LT, with sociodemographic and clinical covariates. Models were stratified by low-risk and intermediate- or high-risk (IR or HR) disease, with a separate interaction analysis between race and risk group. Multivariable Cox proportional hazard ratios compared overall survival (OS) among men who received versus refused LT. RESULTS: Of 887,839 men (median age 64 years, median follow-up 6.14 years), 2,487 (0.28%) refused LT. Among men with IR or HR disease (n = 651,345), Black and Asian patients were more likely to refuse LT than White patients (0.35% v 0.29% v 0.17%; Black v White AOR, 1.75; 95% CI, 1.52 to 2.01; P < .001; Asian v White AOR, 1.47; 95% CI, 1.05 to 2.06; P = .027, race * risk group interaction P < .001). Later year of diagnosis, community facility type, noninsurance or Medicaid, and older age were also associated with increased odds of LT refusal, overall and when stratifying by risk group. For men with IR or HR disease, LT refusal was associated with worse OS (5-year OS 80.1% v 91.5%, HR, 1.65, P < .001). CONCLUSION: LT refusal has increased over time; racial disparities were greater in higher-risk disease. Refusal despite provider recommendation highlights populations that may benefit from efforts to assess and reduce barriers to care.

show abstract

Section: Discussionmentioning

confidence: 99%

Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma

Dee

Arega

Yang

et al. 2021

JCO Oncology Practice

View full text Add to dashboard Cite

show abstract

“…The treatment effect for poorly differentiated GC remains poor (33,61) and it has been demonstrated that poorly differentiated GC is a hotspot in clinical treatment research (35). GC is divided into early GC (stage Ⅰ and Ⅱ) and advanced GC (stage Ⅲ or higher tumors) (36)(37)(38), and there are differences in treatment and surgical methods between early and advanced GC (39,40). Uzun et al (41) revealed that T1-T2 and T3-T4 classifications of patients with GC showed differences in their clinicopathological characteristics and survival status.…”

Section: Discussionmentioning

confidence: 99%

“…According to WHO's fifth edition of gastric cancer differentiation standard (32), the clinical characteristics and prognosis of patients with GC with well-moderately differentiated and patients with GC with poorly-signet differentiated were different (33-35), patients with GC with regards to histological grade were divided into the well-moderately group and poorly-signet group. According to the American Joint Committee on Cancer Staging System (8 th edition) (31), and the differences in treatment and surgical methods between early gastric cancer group (stage Ⅰ and Ⅱ) and advanced gastric cancer group (stage Ⅲ or higher tumors) (36)(37)(38)(39)(40), patients with GC with regards to pathological stage were divided into the early GC group (stage Ⅰ and Ⅱ) and advanced GC group (stage Ⅲ or higher tumors). According to the United States Joint Committee on Cancer Staging System (8 th edition) (31) and the differences between T3-T4 group and T1-T2 classification group with GC in chemotherapy and surgery (41)(42)(43), patients with GC in tumor (T) classification were divided into the T1-T2 and T3-T4 groups.…”

Section: Methodsmentioning

confidence: 99%

hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer

Zhang

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most common cancer and GC has a high mortality rate worldwide. Circular (circ) RNAs serve an important role in cancer. The present study aimed to investigate the expression level of hsa_circ_0060975 in gastric cancer (GC) and to determine the clinical pathological significance of hsa_circ_0060975 in patients with GC. Reverse transcription-quantitative PCR was used to detect expression level of hsa_circ_0060975 in 192 GC and adjacent non-cancerous gastric tissues, in GC cell lines (MKN-45, HGC27 and AGS) and a human gastric epithelium cell line (GES-1), as well as in plasma samples from 126 patients with GC and 92 healthy volunteers. All plasma and tissue samples of were obtained from The First Affiliated Hospital of Anhui Medical University (Hefei, China). The relationship between hsa_circ_0060975 expression and clinical pathological factors was analyzed using the χ 2 test. The diagnostic value of hsa_circ_0060975 was analyzed using the receiver operating characteristic curve (ROC curve), while the Kaplan-Meier method was used to analyze the relationship of hsa_circ_0060975 expression with the survival of patients with GC as determined by log-rank tests. Univariate and multivariate Cox regression analyses were used to identify the prognostic factors, including hsa_circ_0060975 expression and clinical pathological factors. In addition, the potential function of hsa_circ_0060975 was evaluated via bioinformatics analysis. The expression level of hsa_circ_0060975 was higher in GC tissues compared with adjacent non-cancerous gastric tissues, GC cell lines compared with GES-1 and plasma samples from patients with GC compared with plasma samples from healthy volunteers. In addition, higher hsa_circ_0060975 expression was associated with histological grade, pathological stage and tumor (T) classification in GC tissues and plasma samples (P<0.05). The area under the ROC curves of hsa_circ_0060975, the combination with hsa_circ_0060975 and carcinoembryonic antigen (CEA) or CEA alone were 0.804 (sensitivity, 0.746; specificity, 0.783; P<0.001); 0.931 (sensitivity, 0.937; specificity, 0.870; P<0.001) and 0.924 (sensitivity, 0.937; sspecificity, 0.804; P<0.001) respectively. The Kaplan-Meier survival analysis revealed that the overall survival (OS) and disease-free survival (DFS) time of patients with higher hsa_circ_0060975 expression were shorter compared with those in patients with lower hsa_circ_0060975 expression. Univariate and multivariate Cox regression analyses in OS and DFS time determined that the expression level of hsa_circ_0060975, histological grade and pathological stage were independent prognostic factors for patients with GC. In addition, the bioinformatics analysis results suggested that the abnormal expression of hsa_circ_0060975 may serve an important role in tumorigenesis. Hence, hsa_circ_0060975 expression may be an independent prognostic factor for patients with GC and may be a potential marker for biological malignancy.

show abstract

“…Furthermore, the biology of GC be affected by gender. According to the author [79], the male gender was relates to an increased risk of cardiac and noncardiac malignancies. Moreover, the men are more prone to develop proximal GC than women.…”

Section: Demographic Characteristicsmentioning

confidence: 99%

Reducing the Risk of Gastric Cancer Through Proper Nutrition – A Meta-Analysis

Jamil

Palaniappan²,

Zia

et al. 2022

Int. J. Onl. Eng.

View full text Add to dashboard Cite

Abstract— Data Sources: Articles for this paper were sourced from PubMed and Google Scholar databases. Data Extraction: Human studies published in English from 2015 to 2021 were included. Two reviewers initially assessed abstracts of 958 papers and 192 papers were selected for future assessments. After a full review, 38 articles were selected. Results: Dietary salt is a high-risk factor for Gastric Cancer (GC) while red meat and a high-fat diet increase the risk. Alcohol intake is only a risk if consumed heavily. Conclusion: Dairy foods, vitamin C, smoked food, rich food, and Helicobacter pylori are included in the etiology of GC. So are fresh fruits, vegetables, and specific refined grains. Salt, fats, spicy foods, alcohol, red meat, and pepper increase the risk. Knowing cancer patients' nutrition problems would help intervention measures be taken to remedy the situation.

show abstract

Influence of race and sociodemographic factors on declining resection for gastric cancer: A national study

Cited by 10 publications

References 35 publications

Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma

Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma

hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer

Reducing the Risk of Gastric Cancer Through Proper Nutrition – A Meta-Analysis

Contact Info

Product

Resources

About